Earnings Review and Free Research Report: The Medicines Reported Better Than Expected Earnings Results

Research Desk Line-up: Nature’s Sunshine Products Post Earnings Coverage

LONDON, UK / ACCESSWIRE / November 21, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on The Medicines Co. (NASDAQ: MDCO), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=MDCO, following the Company’s announcement of its financial results on October 25, 2017, for the third quarter of the fiscal year 2017. The biopharmaceutical Company’s drug, Vabomere, was granted an accelerated approval by the US Food and Drug Administration (FDA). Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Drugs – Generic industry. Pro-TD has currently selected Nature’s Sunshine Products, Inc. (NASDAQ: NATR) for due-diligence and potential coverage as the Company reported on November 08, 2017, its financial results for Q3 2017 which ended on September 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on Nature’s Sunshine Products when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MDCO; also brushing on NATR. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=MDCO

http://protraderdaily.com/optin/?symbol=NATR

Earnings Reviewed

For the three months ended September 30, 2017, The Medicines’ total net revenues decreased 55.1% to $16.87 million from $37.60 million in Q3 FY16, due to lower sales of the Company’s marketed drug, Angiomax, as a result of a loss in its exclusivity and an increased generic competition. The total net revenue numbers were below analysts’ expectations of $22 million.

During Q3 FY17, the Company’s net product revenues decreased 42% to $10.94 million from $18.84 million in the same period of last year. For the reported quarter, the Company’s royalty revenues decreased 68.4% to $5.94 million from $18.76 million in Q3 FY16.

For the reported quarter, The Medicines’ R&D expenses increased 94.8% to $45.84 million from $23.54 million in Q3 FY16, due to an increased investment in Inclisiran. During Q3 FY17, the Company’s selling, general, and administrative expenses (SG&A) decreased 31.6% to $47.20 million from $69.02 million in the third quarter of 2016. The decrease was due to lower headcount costs and changes to contingent purchase price during Q3 FY17.

During Q3 FY17, The Medicines’ operating loss was $85.77 million compared to an operating loss of $75.74 million in the comparable period of last year.

For the reported quarter, The Medicines’ net loss was $30.18 million compared to a net loss of $86.26 million in Q3 FY16. During Q3 FY17, the Company’s diluted earnings per share (EPS) was negative $0.42 compared to negative $1.23 in the corresponding period of last year. The adjusted net loss excludes share-based compensation expenses, amortization of acquired intangible assets, asset impairment charges, inventory adjustments, restructuring charges, charges associated with product discontinuance, milestone payments, changes in contingent purchase price, expenses incurred for certain transactions, non-cash interest expenses, gain on sale of assets, loss on repurchase of debt, and net loss tax adjustments.

For the reported quarter, The Medicines’ adjusted net loss was $86.33 million compared to an adjusted net loss of $44.80 million in Q3 FY16. During Q3 FY17, the Company’s adjusted diluted EPS was negative $1.19 compared to negative $0.64 in the same period of last year. The adjusted diluted EPS surpassed analysts’ expectations of negative $1.46.

Balance Sheet

As on September 30, 2017, The Medicines’ cash and cash equivalents decreased 69.2% to $166.73 million from $541.84 million as on December 31, 2016.

On August 28, 2017, The Medicines and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced new one-year safety and efficacy data from the ongoing Phase-II study, ORION-1, evaluating pipeline candidate, Inclisiran, for the treatment of hypercholesterolemia. The new data reaffirmed the earlier results from the ORION-1 study, demonstrating significant reductions of LDL-C (low-density lipoprotein) or bad cholesterol at six months and one year.

On August 29, 2017, the Company announced that the FDA had granted an accelerated approval to Vabomere, a combination of meropenem and vaborbactam, for treating complicated urinary tract infections (cUTI), including pyelonephritis.

Stock Performance

At the close of trading session on Monday, November 20, 2017, Medicines Co.’s stock price slightly declined 0.73% to end the day at $31.20. A total volume of 866.06 thousand shares were exchanged during the session. At Monday’s closing price, the stock’s net capitalization stands at $2.24 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 482523